Literature DB >> 18082937

Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.

Kimie Sai1, Yoshiro Saito, Hiromi Sakamoto, Kuniaki Shirao, Koichi Kurose, Mayumi Saeki, Shogo Ozawa, Nahoko Kaniwa, Setsuo Hirohashi, Nagahiro Saijo, Jun-ichi Sawada, Teruhiko Yoshida.   

Abstract

Recent pharmacogenetic studies on irinotecan have revealed the impact of UDP glucuronosyltransferase (UGT) 1A1*28 on severe irinotecan toxicities. Although the clinical role of UGT1A1*6, which is specifically detected in East Asian patients, in irinotecan toxicities is suggested, clear evidence remains limited. To examine the impact of *6, the association of UGT1A1 genotypes with severe irinotecan toxicities was retrospectively investigated in Japanese cancer patients. A significant *6-dependent increase in the incidence of grade 3 or 4 neutropenia was observed in 49 patients on irinotecan monotherapy (p=0.012). This study further clarifies the clinical importance of *6 in irinotecan therapy in East Asians.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18082937     DOI： 10.1016/j.canlet.2007.11.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.

Authors:  Kimie Sai; Yoshiro Saito; Naoko Tatewaki; Masakiyo Hosokawa; Nahoko Kaniwa; Tomoko Nishimaki-Mogami; Mikihiko Naito; Jun-Ichi Sawada; Kuniaki Shirao; Tetsuya Hamaguchi; Noboru Yamamoto; Hideo Kunitoh; Tomohide Tamura; Yasuhide Yamada; Yuichiro Ohe; Teruhiko Yoshida; Hironobu Minami; Atsushi Ohtsu; Yasuhiro Matsumura; Nagahiro Saijo; Haruhiro Okuda
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

3.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

Review 4.  Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology.

Authors:  Christine L H Snozek; Dennis J O'Kane; Alicia Algeciras-Schimnich
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

5.  Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).

Authors:  Goro Nakayama; Ayako Mitsuma; Yuki Sunagawa; Kiyoshi Ishigure; Hiroyuki Yokoyama; Takanori Matsui; Hiroshi Nakayama; Kazuhiko Nakata; Akiharu Ishiyama; Takahiro Asada; Shinichi Umeda; Kazuhiro Ezaka; Norifumi Hattori; Hideki Takami; Daisuke Kobayashi; Chie Tanaka; Mitsuro Kanda; Suguru Yamada; Masahiko Koike; Michitaka Fujiwara; Tsutomu Fujii; Kenta Murotani; Yuichi Ando; Yasuhiro Kodera
Journal:  Oncologist       Date:  2018-07-26

6.  Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project.

Authors:  Keiko Hikino; Takeshi Ozeki; Masaru Koido; Chikashi Terao; Yoichiro Kamatani; Yoshinori Murakami; Michiaki Kubo; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2019-10-04       Impact factor: 3.172

7.  Application of a combination of a knowledge-based algorithm and 2-stage screening to hypothesis-free genomic data on irinotecan-treated patients for identification of a candidate single nucleotide polymorphism related to an adverse effect.

Authors:  Hiro Takahashi; Kimie Sai; Yoshiro Saito; Nahoko Kaniwa; Yasuhiro Matsumura; Tetsuya Hamaguchi; Yasuhiro Shimada; Atsushi Ohtsu; Takayuki Yoshino; Toshihiko Doi; Haruhiro Okuda; Risa Ichinohe; Anna Takahashi; Ayano Doi; Yoko Odaka; Misuzu Okuyama; Nagahiro Saijo; Jun-ichi Sawada; Hiromi Sakamoto; Teruhiko Yoshida
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

8.  Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.

Authors:  Masahito Kotaka; Ruihua Xu; Kei Muro; Young Suk Park; Satoshi Morita; Satoru Iwasa; Hiroyuki Uetake; Tomohiro Nishina; Hiroaki Nozawa; Hiroshi Matsumoto; Kentaro Yamazaki; Sae-Won Han; Wei Wang; Joong Bae Ahn; Yanhong Deng; Sang-Hee Cho; Yi Ba; Keun-Wook Lee; Tao Zhang; Taroh Satoh; Marc E Buyse; Baek-Yeol Ryoo; Lin Shen; Junichi Sakamoto; Tae Won Kim
Journal:  Chin J Cancer       Date:  2016-12-22

Review 9.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors:  Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

10.  Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers.

Authors:  Hiroyuki Moriya; Katsuhiko Saito; Nuala Helsby; Shigekazu Sugino; Michiaki Yamakage; Takeru Sawaguchi; Masahiko Takasaki; Hidenori Kato; Nahoko Kurosawa
Journal:  Oncol Lett       Date:  2014-04-08       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.